Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gamida Cell Ltd (NQ: GMDA )

1.970 +0.020 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 433,799
Open 1.980
Bid (Size) 1.930 (10)
Ask (Size) 2.130 (1)
Prev. Close 1.950
Today's Range 1.920 - 2.030
52wk Range 1.790 - 6.840
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. 
Via InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga

Performance

YTD
-26.22%
-26.22%
1 Month
-11.26%
-11.26%
3 Month
-52.76%
-52.76%
6 Month
-23.94%
-23.94%
1 Year
-70.42%
-70.42%

More News

Read More
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients
Via Benzinga
Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings
Via Benzinga
Gamida Cell: Q4 Earnings Insights
Via Benzinga
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
From Gamida Cell
Via Business Wire
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
From Gamida Cell Ltd.
Via Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Gamida Cell: Q1 Earnings Insights
Via Benzinga
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Earnings Preview: Gamida Cell
Via Benzinga
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
The Daily Biotech Pulse - Tuesday, April,26
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Via Benzinga
Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
From Gamida Cell
Via Business Wire
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.